Trial Profile

A Phase 1b, Multicenter Trial to Evaluate Molecular Determinants of Response to Erlotinib and MK0646 in Advanced Non-Small-Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalotuzumab (Primary) ; Erlotinib (Primary)
Indications Non-small cell lung cancer
Focus Biomarker; Therapeutic Use
Sponsors Merck Sharp & Dohme

Most Recent Events

09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
23 Nov 2010 New source identified and integrated (United Kingdom Clinical Research Network).
21 Jun 2010 Planned end date changed from 1 Jun 2011 to 1 May 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com